Category: Covid-19 Vaccine

Page 640«..1020..639640641642..650..»

Experts Explain The Important Reasons Why COVID-19 Differs From a Flu Pandemic – ScienceAlert

April 3, 2020

"Know thy enemy," Sun Tzu advised in The Art of War. That axiom rings true not just for military strategists, but also for your immune system: Your body might "know" the flu, either from a prior infection or a vaccine.

That familiarity makes the flu easier to vanquish than the novel coronavirus sparking the current pandemic.

Beyond a lack of immunity, testing mishaps and unproven treatments make the novel coronavirus pandemic a new and distinct challenge from influenza outbreaks, which researchers have been working to control for decades.

During flu season even a severe one much of the population is already immune. Your immune system might recognise the viral enemy from a previous infection and pump out antibodies to clear the contagion. Or you might have received a flu shot, a dose of dead influenza viruses that trains your body to fend off a live attack.

People with immunity, whether by infection or injection, help keep the greater public relatively safe from the flu, according to Abigail Carlson, an infectious disease specialist at Washington University in St. Louis.

"When the virus infects them, it reaches a dead end," Carlson told Business Insider. "They don't get sick, they don't pass it on. And they stop the virus in its tracks."

This protective process is called herd immunity. While not perfect tens of thousands of Americans die of flu every year herd immunity generally keeps the flu at levels that hospitals can manage. That's not the case for the new coronavirus.

"There's very little to no herd immunity" with SARS-CoV-2, the virus that causes COVID-19, Carlson said. "Even though the virus might not be extremely deadly, there's a larger number of people who can get infected."

Without herd immunity, humans are ideal hosts for the coronavirus, which has raced across the globe in mere months and encountered few dead ends.

"We're at a point now where the health system is under enormous strain," Carlson said. "Masks are limited, ventilators are limited, beds are limited."

As of Thursday afternoon, the US had recorded more than 236,000 COVID-19 cases and at least 5,600 deaths, according to Johns Hopkins University.

A novel coronavirus vaccine to seed herd immunity is likely more than a year away, and developing it is a tall order compared to configuring the annual flu shot, according to Otto Yang, an infectious disease researcher at UCLA.

First, there's no precursor vaccine to work from: Of the seven coronavirus types that infect humans including four that cause the common cold none has a proven vaccine. Researchers are still seeking how best to craft a vaccine against the new coronavirus, whether by using active virus particles, inactivated ones, or synthetic compounds.

Last month marked the first of many clinical trials another reason Yang believes a COVID-19 vaccine will prove more elusive than the flu shot. The FDA doesn't require clinical trials to approve the annual flu vaccine. Although the exact strains the shot targets vary from year to year, the basic biochemistry stays the same and has proven safe.

So while researchers can fast-track the flu shot each year, they must carefully test any new coronavirus vaccine before offering it to the public. And that's likely to be a lengthy process.

A botched rollout of testing for COVID-19 has also left the US less prepared for the disease than for a flu pandemic, Yang said. To find out if a patient has a viral disease like flu or COVID-19, researchers search for the virus' genes in a swab sample from the patient's nose or mouth.

For the flu, that testing process is reliable. Though the virus mutates, most changes affect proteins on its outer surface, which bind to your cells to initiate an infection. Flu tests target more stable genes that encode for proteins inside the virus' shell.

When it comes to flu, "we have PCR tests that test all the strains," Yang said, adding that the same flu testing procedures are used every year. "All that infrastructure for testing was already in place."

In contrast, figuring out which genes to target in a test for the coronavirus "had to be worked out from scratch," Yang said.

The World Health Organisation developed an effective protocol in January but the US decided to develop its own, and then was slow to produce and distribute it. The lack of testing has hindered researchers' understanding of how widely the disease is spreading.

The US has "failed pretty miserably" when it comes to COVID-19 testing, Yang said. Testing rates in countries like South Korea and Italy are more than double those of the US.

(Ruobing Su/Business Insider)

Patients who do test positive for the novel coronavirus have little choice but to ride out the illness. Antiviral medications that help fight the flu appear to be less effective for COVID-19 patients, Yang said.

"There's no proven treatment at this point for SARS-CoV-2." Some doctors are administering anti-malarial drugs to try and combat the coronavirus, but the efficacy of such treatments is still unclear.

The new coronavirus pandemic poses numerous distinct obstacles compared to the flu. Still, Yang and Carlson see room for optimism as we await a vaccine, because so many people though not everyone are taking social distancing seriously.

"You're really seeing people doing their best to stay at home, stay away from others, and bring that curve down in the US," Carlson said. "Those interventions are working if we just give them a chance Things will get better and this pandemic will indeed pass."

This article was originally published by Business Insider.

More from Business Insider:

Read the original here:

Experts Explain The Important Reasons Why COVID-19 Differs From a Flu Pandemic - ScienceAlert

Coronavirus Vaccine Update: When Will a Covid-19 Vaccine Be Ready? These Programs Are Making Progress. – Barron’s

April 3, 2020

Text size

Social distancing can slow the spread of Covid-19, and new therapeutics could blunt its death toll, but a true return to normalcy is unlikely without a widely-available vaccine.

There are currently at least 47 vaccine programs under way, according to a list kept by the Milken Institute. Below are details on nine of the most notable. Probabilities of success are impossible to gauge, and it will only take one truly successful vaccine to effectively save the world. Here are some to keep an eye on.

Status: Human trials ongoing. First patient dosed on March 16

This is perhaps the most well-known of the Covid-19 vaccine programs. Moderna, a clinical-stage biotech that develops messenger RNA-based vaccines and therapeutics, has already begun dosing patients with its experimental mRNA-based Covid-19 vaccine. Heres an overview of the mRNA-based Covid-19 vaccine programs.

Status: Human trials to begin in April

The German biotech BioNTech is designing another mRNA-based Covid-19 vaccine. It plans to begin clinical trials of the vaccine in April. Outside of China, BioNTech is collaborating on the development of the vaccine with Pfizer. Inside China, the company is working with Fosun Pharma, a Chinese pharmaceutical company.

Status: Human trials to begin in April

Inovios Covid-19 vaccine program drew enormous attention early this year. The company is developing a DNA plasmid vaccine. Inovio says that it plans to start a clinical trial in 30 healthy volunteers in the U.S. next month.

Status: Human trials to begin in late Spring

Novavax, another small biotech that was among the first to announce a Covid-19 vaccine program, is developing a type of recombinant vaccine to prevent Covid-19. In mid-March, it said it had received $4 million to develop the vaccine from the Coalition for Epidemic Preparedness Innovations, a coalition of governments and philanthropies. The company says it expects to begin testing the vaccine in humans in late spring.

Status: Human trials to begin in September

Johnson & Johnson, the worlds largest pharmaceutical company, was one of the first drug developers to announce a Covid-19 vaccine program. On Monday, the company said that the vaccine could be available for emergency use early next year, and that it will start manufacturing it immediately. The company is planning to begin testing the drug in humans by September. It said Monday it planned to make the vaccine available on a not-for-profit basis for emergency pandemic use.

Status: Expects to test in humans by end of 2020

Translate and Sanofi are collaborating on another mRNA-based Covid-19 vaccine, announced late last week. Ron Renaud, Translates CEO, said Friday he hoped to begin testing the vaccine by the end of this year, and hoped for the vaccine to be approved by the second half of next year.

Status: Expects to begin in vitro testing this summer

In addition to its collaboration with Translate, Sanofi is also working on another, previously announced Covid-19 vaccine effort, this one with funding from the Biomedical Advanced Research and Development Authority (BARDA). This program is seeking to develop a recombinant vaccine, as distinct from the mRNA vaccines, and will use Sanofis recombinant DNA platform, which has been used to develop a flu vaccine.

Status: Pre-clinical

Arcturus is working on a Covid-19 vaccine that uses a variation on the messenger RNA approach taken by companies like Moderna and Translate. It is collaborating with the Singapore-based Duke-NUS Medical School, and received a grant for the program from the Singapore Economic Development Board, a government agency.

Status: Pre-clinical

This private German company is also developing an mRNA-based Covid-19 vaccine. Drama has surrounded the company in recent weeks, including allegations that Trump administration officials tried to lure the company to move its research to the U.S., plus shuffles among its top leadership.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Here is the original post:

Coronavirus Vaccine Update: When Will a Covid-19 Vaccine Be Ready? These Programs Are Making Progress. - Barron's

COVID-19 vaccine expected in over a year – WCJB

April 3, 2020

GAINESVILLE, Fla. (WCJB)-- Experts held a COVID-19 Data Science Zoomposium today featuring an employee from the University of Florida.

Biostatistic Assistant Professor Natalie Dean spoke on vaccines and therapeutics.

She says there are over 50 candidates testing their vaccines and predicts it will take around 12 to 18 months before a vaccine for COVID-19 can be used.

One of the challenges is we dont have a animal model, this is an animal that has similar symptoms to humans so we can test the vaccine actually reduces disease and then it goes into these early human trials and then gradually we get a bigger trials that tell whether the vaccine prevents infection to people being exposed, she said.

She says it is very likely the world will still need the vaccine come 2021.

Link:

COVID-19 vaccine expected in over a year - WCJB

CSU researchers rapidly developing treatments, drugs and vaccines for COVID-19 – Source

April 3, 2020

Convalescent plasma

Plasma from those who have recovered from COVID can be used to treat those who have yet to get disease or are early in their disease progression. The plasma contains neutralizing antibodies that can boost a persons immune system to fight the virus. A team of investigators including Ray Goodrich, CSUs executive director of the Infectious Disease Institute and Heather Pidcoke, CSUs chief medical research officer, are collaborating on a project to study the efficacy and potential methods to improve the safety of this repurposed plasma treatment as part of planning for potential clinical trials.

The antibodies in convalescent plasma are specifically made to find the virus and take it out. We are studying pathogen reduction methods that may lower the chance of accidentally giving someone COVID-19 or another infection without meaning to, Pidcoke said. Ultimately we want to protect healthcare workers and other high-risk people from getting sick if they are exposed to the virus that causes COVID-19.

The FDA has already approved a number of individual drugs to treat patients showing symptoms of COVID-19 but use of those drugs in new combinations requires additional approval. CSU researchers have established the use of vero cells to screen cocktails of approved drugs to accelerate the approval process.

CSU researchers have initiated projects with at least six industry partners details to be announced shortly to quickly move these combination drug products toward FDA approval.

A lot of industries are limited with how they can work with the virus, said Rushika Perera, an associate professor of virology who is leading the project to repurpose approved drugs for COVID treatment. They need to partner with CSU to do this research. We have the expertise, labs and physical space.

Vaccines can offer long term protection from COVID-19 and CSU has two vaccine candidates in development.

Solavax repurposes a commercial platform that is currently used to inactivate pathogens in blood transfusions. The strategy uses light and riboflavin to produce an inactivated virus which stimulates a persons immune system to fight the virus.

We are building off of nearly 20 years of experience of using this process to improve the safety of blood transfusion products. That prior knowledge and current experience helps to translate this rapidly into a way to manufacture vaccine products, said Goodrich.

Another vaccine project underway would use a genetically modified form of the common probiotic Lactobacillus acidophilus to avert infection by the novel coronavirus. The concept of this work, led by Gregg Dean, head of CSUs Department of Microbiology, Immunology and Pathology, starts with a microorganism that thrives in the mucous membrane exactly where the new coronavirus attacks the body. The vaccine would interrupt attachment of the virus to host cells at two key junctures, sites that amount to the Achilles heel of the virus, Dean said.

Were fortunate to have such a depth and breadth of expertise in infectious disease here at CSU, he said. Investigators are working on vaccines, on antiviral therapies, on diagnostic strategies, and on how we can inactivate the virus on surfaces. Were trying to tackle this problem from every angle we can.

Go here to read the rest:

CSU researchers rapidly developing treatments, drugs and vaccines for COVID-19 - Source

UW announces new COVID-19 vaccine research, $1.5 million in grants – The Badger Herald

April 3, 2020

The University of Wisconsin announced the development of a COVID-19 vaccine Thursday, and are offering $1.5 million in grants for COVID-19 research and community aid through the Wisconsin Partnership Program.

An international group of virologists at UW, in collaboration with the vaccine companies FluGen and Bharat Biotech, have begun to develop and test an original vaccine against COVID-19 called CoroFlu.

CEO of Wisconsin Alumni Research Foundation Erik Iverson spoke about the project in the news release.

The partners in this endeavor University of Wisconsin researchers, a biotech startup, and an international vaccine developer are moving forward with a sense of urgency and integrity incumbent upon us as scientists and world citizens, Iverson said.

UW predicts $100 million loss due to COVID-19 pandemicThe University of Wisconsin is expecting a $100 million loss due to the ongoing COVID-19 crisis, according to the Wisconsin Read

M2SR is a flu vaccine that activates an immune response against the flu. Based on this invention by UW virologists and FluGen co-founders Yoshihiro Kawaoka and Gabriele Neumann, M2SR will serve as the foundation for the COVID-19 vaccine, according to the news release.

Explained by the news release, Kawaokas lab will work to insert gene sequences from SARS-CoV-2, the coronavirus that causes the disease COVID-19, into M2SR in hopes the new vaccine will also prompt immunity against the coronavirus.

CoroFlu will also express the influenza virus hemagglutinin protein, which is the major influenza virus antigen, so we should get immune responses to both coronavirus and influenza, Neumann said the news release.

According to the news release, refinement of the vaccine and its testing at UW is expected to take three to six months. Bharat Biotech in Hyderabad, India will then produce the vaccine for clinical trials. Bharat Biotech has commercialized 16 vaccines and has the ability to produce almost 300 million doses of CoroFlu per year.

As a result of the expediency of the research, trials and production, CoroFlu could be tested in human clinical trials by fall 2020, according to the news release.

Also in response to the pandemic, a new Wisconsin Partnership Program funding opportunity hopes to aid researchers and community organizations to combat the present challenges facing Wisconsin from the COVID-19 pandemic, according to a news release from UW School of Medicine and Public Health.

Wisconsin Partnership Program University Relations Specialist Anne Pankratz discussed the expeditious turnaround time and communal relief focus of the COVID-19 Grant Program in an email.

COVID-19 Daily Updates: At least 31 confirmed deaths in Wisconsin, 228 confirmed cases in Dane CountyThe Badger Herald will update this article daily as more COVID-19 information comes out. Thursday, April 2. There are now Read

The grant program was developed to help researchers and community organizations address immediate needs and challenges that the pandemic is creating, Pankratz said. It was designed with a brief turn-around time in mind to help address immediate needs, rather than long-term challenges.

COVID-19 Response Grant Program serves as a rapid response mechanism to lessen the impact of the COVID-19 pandemic through scientific, medical or public health approaches, the grant program page said.

According to the Wisconsin Partnership Program, this funding opportunity supports community projects working to improve and protect the health of the people of Wisconsin, with an emphasis on high-risk populations.

We expect that researchers across the UW campus may apply for funding for projects that have the potential to lessen the impact of COVID-19, by focusing on medical and scientific advances as well as public health initiatives, Pankratz said.

According to the Wisconsin Partnership Program, the grant opportunity will fund up to $1.5 million in total awards. $750,000 will go to support community-led projects and the other $750,000 to support projects led by UW researchers. The grant opportunitys award amounts will range from $25,000 and $150,000, for up to 12 months.

Read more:

UW announces new COVID-19 vaccine research, $1.5 million in grants - The Badger Herald

Fighting COVID-19 Is Like ‘Whack-A-Mole,’ Says Writer Who Warned Of A Pandemic – NPR

April 3, 2020

A worker cleans an area along the Las Vegas Strip that's now devoid of the usual crowds, with casinos and many other business shuttered. John Locher/AP hide caption

A worker cleans an area along the Las Vegas Strip that's now devoid of the usual crowds, with casinos and many other business shuttered.

Two years ago, science writer Ed Yong wrote an article for The Atlantic in which he warned that a new global pandemic was inevitable and that the world would be unprepared for it when it arrived. Now, with the outbreak of COVID-19, much of what Yong warned about in his reporting has come true.

Yong says scientists are still working to understand how the novel coronavirus travels through air. His latest article for The Atlantic concerns whether or not people beyond health care workers and other front-line personnel should be wearing some sort of mask to help prevent spread of the coronavirus.

Yong notes that there are two ways in which respiratory viruses typically travel through air: as droplets of fluid and as evaporated specks of fluid called "aerosols."

Yong describes aerosols as "far-drifting" and "long-lasting" viral specks. "There is some growing evidence that aerosol transmission what people would traditionally describe as being 'airborne' does apply, to some extent, to the new coronavirus," he says.

He adds that it's not yet clear whether live infectious viral particles remain in the air where infected people have been: "That's the crucial thing to know," he says. "And then really, crucially, are there enough of those viral particles to actually start an infection? We don't know the answer to that yet."

Yong says the experts he has consulted have not come to a consensus regarding whether or not the general population should wear some sort of mask, when in public places. "There is a lot of movement towards recommending widespread mask usage from different countries," he says. "The CDC appears to be considering it. Health experts I've spoken to who were once dismissive about mask use are now edging towards recommending it."

But Yong adds that the short supply of N-95 respirator masks, and even professionally made surgical masks complicates matters.

"We're currently in a situation where masks are already running out in hospital settings and for health care workers, who are the people who need them the most. So any masks any protective equipment should go to health care workers as a matter of priority. And only then should we think about whether the general population should be considering wearing masks."

Looking ahead, Yong says that even if masks, frequent hand-washing and social isolation strategies are effective in slowing the virus' spread, the end to the pandemic is still a long way off: "We are in for this long, protracted game of whack-a-mole with the virus where different places will stamp it out at different times. It will surge back. It will need to be controlled again."

On what we know about how the virus travels through the air and how we're susceptible to inhaling it

There was one study that just shot virus-laden fluids into a rotating cylinder to create a cloud of aerosols. And they found that within that cloud, the virus remained stable for several hours, which suggests that it can at least survive in the air around us. Now, that's a pretty artificial setup. That's probably closer to a medically invasive procedure like intubation, rather than someone just breathing when they're walking down the street or sitting in a room. So it's hard to know what to make of that outside the health care setting.

But there are other studies that suggest that the coronavirus can be released into the air in less dramatic ways. For example, a new [study] released by the University of Nebraska Medical Center looked for traces of the virus' genetic material in the rooms of several patients who had COVID-19 many of whom only had mild symptoms. So they found traces of that genetic material on lots of different surfaces, including hard to reach spots like ventilation grates and the floors beneath beds. That's consistent with the idea that the virus is moving through the air over distances longer than a droplet might land.

What we don't know is whether there are actually live infectious viral particles in the air. The presence of genetic material doesn't indicate that. It's like finding a fingerprint in a crime scene. It means that the culprit was once there, but they might have long gone. So that's the crucial thing to know. ... And, [in each case], are there enough of those viral particles to actually start an infection? We don't know the answer to that yet. And that's a really crucial piece of the puzzle.

On how thinking about masks for the general population might be changing

Confusion is completely understandable, because even among the experts who I've spoken to including people who've studied airborne transmission and its possibility opinion is divided on the role of masks and how much protection they can provide. There's just a mess of data on whether masks worn by the general population will provide protection against respiratory illnesses in general; whether masks prevent you, if you are infected, from infecting other people. I think that's a little clearer, both from the evidence and just through common sense. And that might matter a lot for a disease like COVID-19.

We know that the virus behind it can spread from one person to another before they show symptoms, and that is perhaps the strongest argument for widespread usage of masks. Even if you aren't currently coughing or sneezing or breaking into a fever, you might not know that you have a virus, and wearing a mask might stop you from spreading that virus to someone else.

On why touching your mask negates its protection

One of the reasons why some people are still on the fence about recommending widespread mask usage is this idea that people who wear masks and aren't used to them kind of futz around with them. They fidget with the masks, they touch their faces. There's not a huge amount of data on this ... but almost everyone I've spoken to who has experience of actually using the masks properly, whenever they've seen people use them in more casual ways, people almost always get it wrong. They pull the mask over their chin, wipe their faces. They touch the masks constantly. They're always adjusting it. And that carries a risk, and maybe the risk is that you do lure yourself into a false sense of security, thinking you're safe, but in a situation when you're actually increasing the likelihood of infection.

On how American hubris and exceptionalism have contributed to the slow response

[A virus] has no interest in people's terror, only their cells. It just wants hosts to infect and doesn't care whether you're feeling brave or not. And I think that some aspects of America's national character do seem to have made it harder for people to take the necessary measures to slow the spread of the pandemic. And not just this sense of resilience, of being brave in the face of fearful threats, but also the sense of individualism and exceptionalism. This idea that "I have the freedom to do what I want to do," which stops people from just staying indoors and heeding advice about isolating yourselves when it's necessary. And I think that the country's famed exceptionalism the idea that this is the greatest country in the world that, I think, contributed to a delay in the nation's response.

The [U.S.] could have sprung into action ready for this, for the virus to eventually reach it. But if anything, America more or less sat idle. It was sluggish. And I do wonder if that propensity to think of itself as being truly exceptional, that slight hubris, left it more unprepared than it needed to be.

Ed Yong

COVID-19 was taking off in China for at least a month before it first reached U.S. shores. And during that month, not much actually happened [in the U.S.]. A lot of preparedness measures could have been launched. The country could have sprung into action, ready for this, for the virus to eventually reach it. But if anything, America more or less sat idle. It was sluggish. And I do wonder if that propensity to think of itself as being truly exceptional, that slight hubris, left it more unprepared than it needed to be. And I think that even though many people had warned about this for a long time, the underwhelming nature of America's response to this threat has really surprised even people who had been warning, who had been issuing alarms.

There is a thing called the Global Health Security Index, which ranks different countries according to their levels of preparedness for pandemics, according to 140 different criteria, based on regulations from the World Health Organization. And out of all the countries that were assessed, the United States has the highest score 83.5, a solid B. But if you look at how the country has actually reacted to the pandemic, I think we probably get something like an F. This nation that was meant to be the most prepared of all has really flubbed its response, and I think, to a degree, that has shocked even the most alarmed or pessimistic people who I'd spoken to before, in my earlier reporting.

On what happened to the medical supply chain for masks and swabs

The medical system runs on a just-in-time economy, much like the rest of the world, and products are made to order and they depend on these very long international supply chains, many of which have fractured in this pandemic. So, for example, Hubei Province, where the pandemic first took off in China, is also one of the world's leading centers for manufacturing medical masks. So the fact that the pandemic hit that region first and hardest really exacerbated the shortage of medical supplies. There's also now a shortage of the swabs that people used to collect viral samples as the very first step of testing. And one of the companies that leads the manufacture of those swabs is based in northern Italy, which is one of the centers of the pandemic in Europe. ...

It's really bad luck that both of those regions were particularly hit, but you could envisage the same problems for all sorts of other areas. I think this is what happens when you rely on a medical system that depends on these large international chains and that really don't have a lot of capacity to flex and surge in the event of a crisis. And that's especially bad now, because the pandemic has spread so quickly that the entire world is facing down the same problem at the same time and is after the same supplies at the same time which really has stretched many of these supply chains to a breaking point. Everyone is after the same supplies and there aren't enough of those supplies to go around. Everyone is competing with each other instead of cooperating, because the crisis has spread so quickly.

On rolling out a COVID-19 vaccine

The first steps so far have actually been encouragingly quick. A vaccine candidate has already entered early safety trials after a record-breakingly short time from actually identifying and sequencing the genome of this new virus. But the journey from these first trials to actually having a product that you can shoot into people's arms is very long and hard to shortcut. You need to know whether the vaccine is safe, whether it triggers an immune reaction. Then you need to know whether it's actually effective at preventing infections. You need to know what dose to use, how many doses to use, whether it also works in elderly people who are more at risk. All of these steps take time, and if you don't go through them, you might run the risk of creating a product that has really severe side effects or that is rolled out widely but just doesn't work.

So the experts I've spoken to feel that it will probably take between 12 and 18 months to even develop a working vaccine, let alone then to create the manufacturing capacity to create enough doses and then to distribute those doses and to actually inject them into people. This is not going to be a fast process. And until that process is complete, COVID-19 is going to be a part of our lives.

On the different methods being used to develop a vaccine for COVID-19

Most existing vaccines [against other viruses] use a dead or weakened virus or a fragment of that virus. So the idea is, you show that to the immune system, [and] the immune system can prepare defenses ahead of time. [One new vaccine candidate in development against the coronavirus] works in a slightly different way. It uses a piece of the virus' genetic material, its RNA. You inject that up into a person in the hope that that person then can build their own fragments of the virus using the instructions in that genetic material and that those sorts of homegrown fragments can then train the immune system. These RNA vaccines are a new technology. They have the potential to be really important and to be much faster. But the caveat is that no such vaccines have ever been taken to the market before. So we're breaking new ground and there aren't facilities already available that can manufacture such vaccines in the quantities that are needed.

By contrast, other teams are using more traditional approaches. For example, there's one group in France that is trying to repurpose the existing measles vaccine to instead target the new coronavirus. That might take a longer time at the front end. But on the plus side, if that actually works, then the world knows how to make measles vaccines in large quantities. So it's unclear which of ... these solutions will end up being quickest. But it's certainly reassuring that a lot of different options are being tried not just these two, but but many others. And we'll just have to wait and see which gets to the finish line soonest.

On the idea that the spread of the coronavirus might slow down in the summer

So, traditionally, coronaviruses and a lot of other respiratory viruses, like flu, do go away in the summer, and there are many possible reasons for that. Certainly, humidity and heat makes it easier for the cells of our airways to clear out a virus, and some of the immune response to these respiratory viruses appear to be stronger under those climatic conditions.

Now, is this new coronavirus going to behave in the same way? Possibly. Is that going to make a difference with the pandemic? I'm not sure. And the reason for that is that the virus is circulating through a global population that is completely immunologically naive to it. Our immune systems are not ready to deal with something like this. And so the virus has a large proportion of hosts among whom it can easily spread. To hope that the summer is going to downplay those dynamics far enough to contain the pandemic is, I think, wishful thinking. ... We're seeing transmission in places like Australia, which is just coming out of its summer, or Singapore, which is hot and humid in the tropics. And what that tells us is that it's probably wishful thinking to hope for heat and humidity to be the things that contain this virus. They may help, but only if we can slow its spread in other ways, such as through social distancing.

On being prepared for COVID-19 to come back

I think that's very likely. I think most experts would expect some kind of resurgence once current social distancing measures are released. That's sort of in the nature of these viruses. It's definitely likely because the pandemic is now so widespread that unless the entire world simultaneously brings the virus to heel, there are always going to be pockets where outbreaks are still ongoing, and that can seed [and] can reignite sparks of infection in places where outbreaks had already been extinguished. ...

And so we're likely looking at multiple rounds of social distancing, multiple bouts of social upheaval. Now, it's possible if we get our act together and if we do well in this first wave, that those subsequent bouts will be less dramatic and less uprooting than this current period of time has been, and that may well just be because of that uneven spread. So currently the virus is everywhere. It's hitting everywhere ... at more or less the same time. If different places can get it under control, there might be less potential for that sort of explosive worldwide spread. And then, over time, one would hope that surveillance measures would be better. We become better at testing for the virus and working out who's immune to it, at building up the necessary supplies to protect health care workers. All of those measures might mean that we can get a little bit more sophisticated in where social distancing is being rolled out, in the nature of those measures. But I think it's very clear that that is going to be a long game.

Pandemics often expose existing fault lines in societies, and they reveal whom a society cares about and whom it often ignores.

Ed Yong

On how the pandemic has hit society's most vulnerable

Clearly, the economic implications of this are going to be profound. I think, as with many disasters, it's going to hit people in different ways that are magnified by existing inequalities; people from low income groups, people from marginalized groups are going to feel the effects of this far more.

Pandemics often expose existing fault lines in societies, and they reveal whom a society cares about and whom it often ignores. The people who are still having to serve on the front lines of society while everyone else is sheltering indoors, people like grocery store workers, janitors, they are currently risking their lives because many of them don't have a choice. The elderly who have often been marginalized in the fringes of society are now [being asked to] isolate themselves even more, deepening the loneliness that many of them have already felt. People with mental health disorders, people with anxiety and obsessive compulsive disorder who have long been grappling with worries about infection and cleanliness, are now seeing some of their worst nightmares playing out around them and are struggling in a context where they don't have access to their usual support networks or therapists.

So a lot of societal dynamics which were already being overlooked and which were already fraying are going to fray even more. I think it's important to be wary of [that unraveling] and to look out for the people who are most going to need help. A pandemic causes a wave of physical suffering, but following that, there is also economic suffering, mental suffering, emotional suffering. We will need to be wary of all of those things when society rebuilds in the wake of this crisis.

On the potential of the pandemic to inspire positive change

I think that this is the time to be imagining what a better world might look like and to start actively working towards it. These periods of great social upheaval carry with them great risk and tragedy, but also great potential. So on a very simple level, after HIV spread throughout the world and the '80s, it led to better awareness of sexual health that led to mainstreaming of condom use, of testing [for sexually transmitted infections]. And perhaps the COVID-19 pandemic will lead to a normalization of health behaviors that have been quite difficult to get people to take up, like regular hand-washing for 20 seconds sometimes a rarity even in hospital settings, let alone in homes. And now all of us well, many of us, hopefully [are] washing our hands on a regular basis every day. Hopefully that will become a normal part of our culture in the future.

I also really hope that a lot of the ethic of cooperation that we're starting to see, of people in communities looking out for each other, coming together at a moment of crisis, will continue through the rest of this long-haul pandemic and beyond. I think we're going to need that if we're going to be better-prepared for what's to come. We need that sense of cooperation between neighbors in a community, between states, in a country and between countries an international community.

Amy Salit and Seth Kelley produced and edited the audio of this interview. Bridget Bentz, Molly Seavy-Nesper and Deborah Franklin adapted it for the Web.

Read the original here:

Fighting COVID-19 Is Like 'Whack-A-Mole,' Says Writer Who Warned Of A Pandemic - NPR

COVID 19: U.S. says that Ultimate Game Changer Vaccine is on the Way – Yahoo Finance

April 3, 2020

By Gina Lee

Investing.com-Australia announced a $973 million package for its childcare sector.

Japans government debated an economic packageincluding ECMO machines.

The United States is on target to develop aCOVID-19 vaccine with biotech company Modernawithin 12 to 18 months.

As ofApril 1,thenumber of confirmed cases globally stood at827,419with40,777deaths, according to the World Health Organisation.

Australia

Prime Minister Scott Morrison announced an A$1.6 billion ($973 million) package for the countrys13,000-strongchildcare sector over the next three months.

The services will be rendered free of charge as theywill be paid from taxpayer subsidies.

Japan

The government is mulling the increased production of extracorporealmembranousoxygenation (ECMO) machinesas part of an economic package to combat COVID-19.

The machines will replace a persons breathing to supply oxygen and remove carbon dioxide.

United States

White Househealthadvisor Anthony Fauci announcedovernightthat the first human trialto test a potential COVID-19 vaccine is on target and will be an ultimate game changer.

Biotech company Moderna is working with Fauci and other healthofficialsto develop the vaccine. Human trials started on March 16.

The vaccine is estimated to bedistributedwithin 12 to 18 months, with phase two trials expected to begin in a few months.

Related Articles

WHO expects Malaysia's coronavirus cases to peak in mid-April

Latest on the spread of the coronavirus around the world

Boeing to offer voluntary layoffs to employees to tide over coronavirus fallout -sources

Visit link:

COVID 19: U.S. says that Ultimate Game Changer Vaccine is on the Way - Yahoo Finance

The race to develop Covid-19 drugs and vaccines is on here’s what’s happening in the UK – Endpoints News

April 3, 2020

Weeks away from the results of ongoing US and China trials testing its experimental antiviral remdesivir, Gilead is going to trial the failed Ebola drug in a small group of coronavirus patients in England and Scotland. The United Kingdom is also home to a range of other therapeutic efforts, as the pandemic rages on across the globe.

On Tuesday, Southampton, UK-based startup Synairgen kicked off a mid-stage placebo-controlled study testing its experimental drug, SNG001 an inhaled formulation of interferon-beta-1a that has previously shown to be safe and effective in improving lung function in asthma patients with a respiratory viral infection in a pair of Phase II trials.

Interferons, a family of naturally occurring proteins secreted by the immune system, typically boost the bodys immune response to uninvited guests such as viruses, bacteria and cancer.

When weve collected cells from patients with COPD and asthma and older peoplewe find that their lung cells dont respond very well to viruses, CEO Richard Marsden said in an interview. We have also along the way always recognized that with an emerging virus, the drug could be used.

As Covid-19 started to gather steam in China, Synairgen tried to get things started, but to no avail. Italy was the next plan. We had some really good interaction there, said Marsden. But they went from, you know, just busy to very busy to extremely busy to unable-to-communicate busy.

Eventually, they decided their home ground the UK, where they have an ongoing COPD trial would be the best place to kick off a Covid-19 study. Initially, the pilot phase of the trial will have 100 patients (50 will get a placebo, and 50 will get SNG001). If all goes well, a pivotal study will be conducted.

This approach is one of many, as companies race to design and develop diagnostics, drugs and vaccines to stem the tide of the pandemic. (W)e need high quality clinical research to work out what is working, what isnt working; we believe placebo-controlled trials are the way to do that, Marsden said.

Last week, the UK government issued a statement confirming that the two decades-old malaria drugs: chloroquine and hydroxychloroquine, which have been touted as potential treatments for patients infected with the coronavirus, have not been sanctioned for use against the virus in the UK.

Although clinical trials are ongoing, no conclusions have been reached on the safety and effectiveness of these medicines, noted the Medicines and Healthcare products Regulatory Agency. In stark contrast, in the United States, the FDA on Sunday issued emergency authorization for the pair of drugs that President Donald Trump has repeatedly backed, on the basis of anecdotal reports.

In the UK, scientists at Oxford University are also looking at repurposing other drugs for use against Covid-19. Last week, researchers announced they would be testing lopinavir-ritonavir, approved used to treat HIV, and the steroid dexamethasone, in consenting adults that have tested positive for Covid-19 in NHS hospitals. The project, in which patients will either get one of the two drugs, or placebo in addition to standard-of-care treatment, has won 10.5 million in government funding.

The streamlined design of this clinical trial allows consenting patients to be enrolled in large numbers easily and without compromising patient safety or adding significantly to the workload of busy hospitals and their staff, said the trials deputy chief investigator Martin Landray, who also serves as a professor of medicine and epidemiology University of Oxford, in a statement.

Oxford researchers also have a vaccine candidate in place.

On January 10 long before the coronavirus infection was named Covid-19 or assumed pandemic proportions a team of Oxford researchers led by Professors Sarah Gilbert, Andrew Pollard, Adrian Hill and Dr. Sandy Douglas had begun their search for a vaccine. On March 18, they honed in on a candidate: a chimpanzee adenovirus vaccine vector (ChAdOx1).

Chimpanzee adenoviral vectors are well studied, having been used in vaccines targeting over 10 different diseases. The Oxford vaccine contains the genetic sequence of the surface spike protein found on SARS-CoV-2 the virus behind Covid-19 inside the ChAdOx1 construct. If the project is successful, vaccination with this product will produce the surface spike protein of the coronavirus, priming the immune system to attack the coronavirus if it later infects the body.

The researchers who have previously developed a vaccine for MERS that showed promise in early clinical trial said last week they would start screening people for a clinical trial, although the vaccine is still weeks away from being ready for human testing. The enrollment goal is to hit 510 volunteers, and work is being done to scale up manufacturing in haste.

About a two-hour drive away, researchers at the University of Cambridge also have a Covid-19 vaccine in the works.

Professor Jonathan Heeney, head of the laboratory of viral zoonotics and chief of spinoff company DIOSynVax, has spearheaded research, aided by computer modeling of the virus structure.

By putting the genetics of the virus under a microscope, the company has identified a key part of the genetic code that the virus uses to produce the essential part of its coat: the spikes, which is what the vaccine is engineered to target.

A vaccine strategy needs to be laser specific, targeting those domains of the virus structure that are absolutely critical for docking with a cell, while avoiding the parts that could make things worse, he said in a statement. Our technology does just that.

Preclinical trials are yet to be conducted, but he expects the vaccine candidate could be ready for human trials by June. Funding, however, is required.

We need a Big Pharma partner to help us scale up our activities, he said.

For a look at all Endpoints News coronavirus stories, check out our special news channel.

More:

The race to develop Covid-19 drugs and vaccines is on here's what's happening in the UK - Endpoints News

Over 35 Companies in Race to Develop Vaccine for COVID-19 – All On Georgia

April 1, 2020

The race is on as a number of companies around the globe are fighting for the chance to be first to develop a COVID-19 vaccine.

The World Health Organization has announced that while the search for treatments of COVID-19 continues, even some of the more draconian containment initiatives have only slowed the spread of the virus. Thats why companies are working around the clock to create a vaccine before, as some worry, the virus mutates again.

Financialnewsmedia.com reports:

According to The Guardian, about 35 companies and academic institutions are racing to create such a vaccine, and Human trials will begin imminently but even if they go well and a cure is found, there are many barriers before global immunization is feasible. This unprecedented speed is thanks in large part to early Chinese efforts to sequence the genetic material of the virus.Chinashared that sequence in early January, allowing research groups around the world to grow the live virus and study how it invades human cells and makes people sick.

Active healthcare stocks in news today include: BioSig Technologies, Inc.(NASDAQ:BSGM),Gilead Sciences, Inc. (NASDAQ:GILD), CytoDyn Inc.(OTCQB:CYDY), Novavax, Inc. (NASDAQ:NVAX),Roche Holding AG(OTCQX:RHHBY).

Clinical trials, an essential precursor to regulatory approval, usually take place in three phases. The first, involving a few dozen healthy volunteers, tests the vaccine for safety, monitoring for adverse effects. The second, involving several hundred people, usually in a part of the world affected by the disease, looks at how effective the vaccine is, and the third does the same in several thousand people. But theres a high level of attrition as experimental vaccines pass through these phases. Not all horses that leave the starting gate will finish the race, saysBruce Gellin, who runs the global immunization program for theWashington DC-based nonprofit, theSabin Vaccine Institute.

The Guardian also reported:

Though nobody could have predicted that the next infectious disease to threaten the globe would be caused by a coronavirus flu is generally considered to pose the greatest pandemic risk vaccinologists had hedged their bets by working on prototype pathogens. The speed with which we have [produced these candidates] builds very much on the investment in understanding how to develop vaccines for other coronaviruses, saysRichard Hatchett, CEO of theOslo-based nonprofit theCoalition for Epidemic Preparedness Innovations(Cepi), which is leading efforts to finance and coordinate Covid-19 vaccine development.

According to a news release, CytoDyn Inc.recently announced that an additional three critically ill COVID-19 patients have been treated with leronlimab. These additional patients increase the total to 10 patients receiving leronlimab treatment under an Emergency Investigational New Drug (EIND) granted by the U.S. Food and Drug Administration (FDA).

Originally posted here:

Over 35 Companies in Race to Develop Vaccine for COVID-19 - All On Georgia

A Creator of the Ebola Vaccine Has Hope for Slowing Covid-19 – WIRED

April 1, 2020

When the late Bob Simon interviewed Gary Kobinger for 60 Minutes in 2015, Kobinger was working principally in a space suit in a special clean room behind bulletproof glass. At the time, he was a top virologist at Canadas National Microbiology Lab, where he became a critical player in the development of the early Ebola vaccine ZMapp. Now hes the director of the Infectious Disease Research Center at the Universit Laval in Quebec City, his hometown. His lab helped with the early development of Inovio Pharmaceuticals Zika vaccine in 2017.

Today, Kobinger is among hundreds of scientists worldwide working on potential Covid-19 vaccines; he is working with Inovio and Medicago, another drug company. WIRED talked with Kobinger by phone last week. The conversation has been condensed and edited.

WIRED: You've been watching and helping with epidemics your entire career. How does Covid-19 compare to, say, the Ebola epidemic?

GARY KOBINGER: Well, it's on a global scale of course, so its more widespread than Ebola. But its also important to remember that this virus has a less than 5 percent fatality rate, versus 80 percent for Ebola before vaccines. [There were 28,652 Ebola cases during the 2014-2016 outbreak in West Africa and 11,310 deaths, according to the Centers for Disease Control and Prevention. There are more than 775,000 Covid-19 cases, according to Johns Hopkins University. It has killed more than 37,000 people.]

But pandemics are so similar in the way societies respond. I went to many different countries in Africa because of Ebola outbreaks. And often we were accused of being the ones bringing in the virus and infecting the population. We have the same thing today, where countries are saying its the Army or a secret Defense Department plan or whatever to export the virus.

Read all of our coronavirus coverage here.

We also see the same delays. Theres this natural optimism of societies, where you think the virus isnt going to come here, and you end up facing exactly the same last-minute urgent needs for things like PPEs [personal protective equipment like masks and gowns]. China had problems with PPEs in mid-January. So you could argue that we should have planned for that. Instead we are scrambling as if we never saw it coming.

The difference this time is, because Covid-19 is affecting so many countries, you see a lot more sense of urgency to develop countermeasuresvaccines, treatments, better supportive care like ventilators. Compare that to being in the middle of the tropical forest in Africa, like we were with Ebola. We would have liked to have had all that fancy equipment. But people were not that interested in what we were doing. With Covid-19, Ive had all levels of the Canadian government coming to me, saying, Gary, if you need anything, please let us know. We are here to help. I've never had that kind of support in my career.

There are dozens of labs worldwide working on a Covid-19 vaccine, including yours. Is that a good thing, or should we be coordinating and focusing that effort more to maybe get a vaccine faster?

Its a good thing. Its actually important to test a lot of vaccines. We dont want to put all our eggs into one basket, only to have that one vaccine fall short in clinical trials. If we could have five vaccines that are safe and work and are potent, that would be much better. It also reduces the chances for manufacturing bottlenecks. With five vaccines, maybe we could manufacture enough for everybody on the planet. But with only one manufacturer, I dont think it will be possible.

But it needs to be done the right way. If you develop a vaccine thats not powerful enough to counter the virus, it can actually make the infection harder to treat. What you could see are people becoming more susceptible to acquiring the infection and maybe more susceptible to severe disease. That's something to really watch out for.

"Its actually important to test a lot of vaccines."

Gary Kobinger, virus researcher

Whats clear is that the development is going to be expensive. If we had done this work ahead of time, we could have done it for $500 million to $800 million. Now we're spending billions of dollars because we're rushing, in an emergency. When the virus was first emerging in China, I said this has the potential to show our level of preparedness. We will probably realize we are not very ready for this kind of event.

Is there any way to speed the development, which is expected to take at least 18 months? Thats a long time.

Yes. With some government and regulatory coordination, we can be faster than 12 months rolling out a vaccinenot for the planet, but maybe for target populations like health care workers. You could also target vulnerable populations like the elderly or those with co-morbidities by doing risk analysis for each of those populations. The track we are on nowwith a vaccine that needs to work for everybody with no side effectsis slower. We'll see. With Ebola in West Africa, we saw things happenpeople working together, work that got donethat were unprecedented. I hope we are in another of those moments.

What about therapies? If we made Covid-19 less lethal, that could do almost as much as a vaccine and provide relief much faster.

You need bothdevelop therapies and vaccines. Therapies are important, but you have to be reasonable with your expectations. You have to be very careful about creating false hope with therapies. On one hand, if you dont have a randomized trial, its hard to make any claim about their effectiveness. At the same time, its important to listen to health care workers who are using those drugs on the front lines. They have a very good sense of what may be worth pursuing and not pursuing in trials, even if they are not using it in a randomized trial. So with drugs like chloroquine and azithromycin that are already approved, lets put them in the clinic as soon as possible, and at same time design the best clinical study you can.

"It will get worse before it gets better, but a lot of the control measures are working."

Gary Kobinger, virus researcher

But the ultimate goal is to find a vaccine that keeps people from getting the virus at all. Sometimes patients who get it are left with lung damage that's not repairable. And even if the virus recedes, it could come back worse later. In 1918 the Spanish flu in the spring was a very mild wave, and then it came back with a vengeance in the fall.

Read more:

A Creator of the Ebola Vaccine Has Hope for Slowing Covid-19 - WIRED

Page 640«..1020..639640641642..650..»